



ABN 53 075 582 740

ASX ANNOUNCEMENT
24 September 2020

APPOINTMENT OF TWO NEW DIRECTORS

Bionomics Limited (ASX: BNO, OTCQB:BNOEF), a global, clinical stage biopharmaceutical company, announced today that Dr Srinivas Rao and Dr Jane Ryan have been appointed Non-Executive Directors to the Board of Bionomics Limited from 1 October 2020.

Dr Rao is the Chief Scientific Officer at ATAI Life Sciences AG. Dr Rao has over 19 years of professional experience in the pharmaceutical and biotechnology industries. Prior to ATAI, Dr. Rao has held the titles of Chief Scientific, Medical, or Executive Officer at companies ranging from venture backed start-ups to vertically integrated, publicly traded pharmaceutical companies. Dr. Rao completed an internship in Internal Medicine at Yale-New Haven Hospital. He received his Ph.D. in neurobiology from Yale Graduate School and his M.D. from Yale School of Medicine. He holds both a Bachelor of Science and Master of Science degree in Electrical Engineering from Yale College and Yale Graduate School, respectively.

Dr Rao is the second Board nominee of Apeiron Investment Group Ltd ("Apeiron") under the Subscription Agreement dated 1 June 2020 between the Company and Apeiron, following completion of the second placement of 54,333,000 to Apeiron and their nominated exempt investors.

Dr Ryan has over 30 years of international experience in the pharmaceutical and biotechnology industries having worked in Australia, US and UK. She has held senior executive roles in management of research and development programs as well as business development and alliance management. Throughout her career, she has led many successful fundraising campaigns and licensing initiatives including the awarding of a \$230m US Government contract. Jane is currently a Non-Executive Director of Anantara Lifesciences Ltd.

Dr Ryan will replace Mr Peter Turner who has decided not to stand for re-election at the November 2020 AGM. Under the Corporations Act 2001, the Company must have at least two Directors who ordinarily reside in Australia

The Executive Chairman of Bionomics Limited, Dr Errol De Souza said "We welcome both Dr Rao and Dr Ryan to the Board. Dr Rao's background in psychiatry and experience in the pharmaceutical and biotechnology industries together with Dr Ryan's extensive pharmaceutical development experience in the life sciences sector makes them an excellent addition to the Board as we progress BNC210 into Phase 2b trials for the treatment of post-traumatic stress disorder"

AUTHORISED BY THE BOARD.

FOR FURTHER INFORMATION PLEASE CONTACT:

Mr Jack Moschakis
Legal Counsel & Company Secretary
+61 8 8354 6181
jmoschakis@bionomics.com.au

About Bionomics Limited

Bionomics (ASX: BNO) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates. Bionomics' lead drug candidate BNC210, currently in Phase 2 for the treatment of agitation, is a novel, proprietary negative allosteric modulator of the alpha-7 ($\alpha 7$) nicotinic acetylcholine receptor. Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada) and a pipeline of pre-clinical ion channel programs targeting pain, depression, cognition and epilepsy.

www.bionomics.com.au